Increased levels of soluble cell adhesion molecules (sCAM) have been reported in HIV-1 infection and may possibly contribute to altering the adhesion mechanisms of phagocytic cells. We evaluated the effect of highly active antiretroviral therapy (HAART) on plasma levels of sl-selectin, sE-selectin, intercellular cell adhesion molecule-1 (sICAM-1), sICAM-3, and vascular cell adhesion molecule-1 (sVCAM-1). Study participants included 22 HIV-1-infected patients with a CD4(+) T-cell count/mu l below 500 who were started on a HAART regimen and followed up for 9 months. After the initiation of therapy, plasma sl-selectin concentrations progressively decreased to normal ranges in the majority of our patients (P < 0.001), while no changes in sE-selectin were found. In all patients sICAM-1 remained relatively constant at significantly elevated concentrations during the 9 months of therapy. A significant reduction in plasma concentrations of both sICAM-3 and sVCAM-1 was found; however, the levels of these sCAM were not normalized by HAART and remained significantly elevated throughout the study (P < 0.001). The reduced release of sL-selectin could improve the ability of phagocitic cells to migrate in response to chemotactic stimuli after starting HAART. On the other hand, the persistent elevation of sICAM-1, sICAM-3, and sVCAM-1 could reflect continuous HIV-1-mediated immune activation, despite adequate control of plasma HIV-1 replication by therapy. (C) 2000 Academic Press.

Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients / Mastroianni, Claudio Maria; Lichtner, Miriam; Fabio, Mengoni; Claudia, D'Agostino; D'Ettorre, Gabriella; Gabriele, Forcina; Paola, Santopadre; Massetti, Anna Paola; Vullo, Vincenzo. - In: CLINICAL IMMUNOLOGY. - ISSN 1521-6616. - 95:3(2000), pp. 212-217. [10.1006/clim.2000.4865]

Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients

MASTROIANNI, Claudio Maria;LICHTNER, Miriam;Gabriella D'Ettorre;MASSETTI, Anna Paola;VULLO, Vincenzo
2000

Abstract

Increased levels of soluble cell adhesion molecules (sCAM) have been reported in HIV-1 infection and may possibly contribute to altering the adhesion mechanisms of phagocytic cells. We evaluated the effect of highly active antiretroviral therapy (HAART) on plasma levels of sl-selectin, sE-selectin, intercellular cell adhesion molecule-1 (sICAM-1), sICAM-3, and vascular cell adhesion molecule-1 (sVCAM-1). Study participants included 22 HIV-1-infected patients with a CD4(+) T-cell count/mu l below 500 who were started on a HAART regimen and followed up for 9 months. After the initiation of therapy, plasma sl-selectin concentrations progressively decreased to normal ranges in the majority of our patients (P < 0.001), while no changes in sE-selectin were found. In all patients sICAM-1 remained relatively constant at significantly elevated concentrations during the 9 months of therapy. A significant reduction in plasma concentrations of both sICAM-3 and sVCAM-1 was found; however, the levels of these sCAM were not normalized by HAART and remained significantly elevated throughout the study (P < 0.001). The reduced release of sL-selectin could improve the ability of phagocitic cells to migrate in response to chemotactic stimuli after starting HAART. On the other hand, the persistent elevation of sICAM-1, sICAM-3, and sVCAM-1 could reflect continuous HIV-1-mediated immune activation, despite adequate control of plasma HIV-1 replication by therapy. (C) 2000 Academic Press.
2000
adhesion molecules; anti-hiv-1 therapy; innate immunity
01 Pubblicazione su rivista::01a Articolo in rivista
Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients / Mastroianni, Claudio Maria; Lichtner, Miriam; Fabio, Mengoni; Claudia, D'Agostino; D'Ettorre, Gabriella; Gabriele, Forcina; Paola, Santopadre; Massetti, Anna Paola; Vullo, Vincenzo. - In: CLINICAL IMMUNOLOGY. - ISSN 1521-6616. - 95:3(2000), pp. 212-217. [10.1006/clim.2000.4865]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/251219
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact